Custom Supplement Formulation: From Brief to Production Record

A good first sample can still become a bad commercial product.

The sample may taste right but bridge in a hopper. A capsule may fit at bench scale but miss its fill-weight range at line speed. A flavor may pass on day one and fade after three months in a warm warehouse.

Custom supplement formulation is the work of closing those gaps before the first production order. The endpoint is not a jar from the lab. It is a formula, process, specification, package, and record set that another trained team can reproduce.

Gate 1: Write the commercial brief

Start with constraints, not an ingredient wish list.

The formulator needs to know:

• target consumer and market;
• intended benefit and proposed claims;
• dosage format;
• serving size and units per serving;
• ingredients that must be present or excluded;
• target retail price or cost ceiling;
• first order and annual forecast;
• sales channel; and
• packaging and shelf-life target.

These fields expose conflicts early. A brand may want six high-dose minerals in one small capsule, a clear liquid containing poorly soluble botanicals, or a naturally flavored powder with no sweetener and no bitterness. Those are formulation problems, not artwork problems.

If the brief is still vague, use the checklist in How to Brief a Contract Manufacturer before requesting a sample.

Gate 2: Screen ingredients and claims

Each ingredient needs an identity, source, specification, dose, and regulatory rationale for the target market. Supplier marketing sheets are not enough.

For a U.S. launch, the review should include at least:

• whether every component is suitable for use in a dietary supplement;
• whether an ingredient may raise a new dietary ingredient question;
• supplier documentation and test methods;
• allergen and dietary-positioning conflicts; and
• whether the proposed claims match the formula and available substantiation.

When a new dietary ingredient notification is required, FDA guidance describes a submission at least 75 days before interstate marketing. That timing can change the critical path, so it belongs in the first review, not at label approval. See the FDA's NDI notification procedures and timeframes.

Claims need equal discipline. The FDA distinguishes structure/function claims from disease claims, and the FTC expects objective health advertising claims to be truthful, not misleading, and supported before they are published. The relevant starting points are the FDA structure/function claim guidance and the FTC Health Products Compliance Guidance.

Gate 3: Run a format-feasibility check

The same formula behaves differently in every format.

Format	Questions to answer before sampling
Capsule	Will the blend fit the shell count? Does it flow and hold content uniformity?
Tablet	Can it compress without capping, sticking, or slow disintegration?
Powder	Will it disperse, taste acceptable, and resist caking?
Liquid	Are the actives soluble or suspendable? Is the system physically and microbiologically stable?
Softgel	Is the fill compatible with the shell? How will oxidation and seam integrity be controlled?
Daily pack	Do the component formats and package sequence run reliably together?

This gate is where a formulator chooses excipients for a reason: flow, lubrication, disintegration, suspension, taste masking, moisture control, or oxidation protection. "Clean label" restrictions must be stated here because removing a functional excipient usually creates a process tradeoff.

Gate 4: Define the sample question

Do not ask a prototype to answer everything at once. Each round should have a written question.

Examples:

• Can the target active load fit into two size-00 capsules?
• Which of two flavor systems masks the mineral note at the planned serving weight?
• Does the liquid remain uniform through the expected consumer-use period?
• Can the tablet reach the required hardness and still disintegrate on spec?

Record the formula version, raw-material lots, process, sample date, and evaluation result. "Version 3 tastes best" is not enough if no one can reconstruct Version 3.

Gate 5: Lock the product specification

Once the concept is acceptable, convert preferences into measurable acceptance criteria. The specification may cover:

• identity and composition;
• potency or marker compounds;
• microbiological and contaminant limits;
• unit weight or fill weight;
• appearance, odor, flavor, and color;
• hardness, friability, disintegration, viscosity, or water activity where relevant;
• packaging configuration; and
• storage condition and shelf-life plan.

The test panel should follow the risks of the formula and format. It should not be copied from an unrelated SKU.

Gate 6: Scale the process, not only the ingredient list

Bench equipment hides problems that appear on a commercial line. Scale-up confirms order of addition, blend time, screen size, hold time, line speed, in-process checks, expected yield, and acceptable adjustment limits.

For dietary supplements, the FDA CGMP framework requires a written master manufacturing record for each unique formulation and batch size, plus a batch production record for every batch. The FDA's Part 111 small-entity compliance guide explains the required production and quality documentation.

This is why "same formula, larger batch" is not a complete scale-up plan. The record must describe how the batch will actually be made and controlled.

Gate 7: Approve label, package, and stability together

The package is part of the formulation system. A moisture-sensitive powder in a low-barrier package or an oxidation-sensitive oil with excessive headspace can fail even when the initial assay is correct.

Approve these as one set:

• final formula and serving size;
• Supplement Facts and ingredient list;
• claims and directions;
• container, closure, liner, and desiccant where applicable;
• lot and date coding;
• finished-product specification; and
• stability protocol.

FDA's dietary supplement labeling guide identifies five core label statements. Build the artwork from the approved formula, not from the first concept deck.

What the brand should receive at handoff

A controlled handoff is easier to transfer, reorder, investigate, and improve. Ask what you will receive and what the manufacturer retains:

Deliverable	Why it matters
Approved formula and version	Prevents silent changes between sample and production
Raw-material specifications	Defines the inputs actually qualified
Finished-product specification	Defines release, not just appearance
Packaging bill of materials	Keeps component changes visible
Approved label	Connects formula, claims, and market presentation
Certificate of analysis	Shows released results for the batch
Stability protocol and reports	Supports shelf-life decisions
Change-control route	Defines who approves future substitutions or revisions

Ownership and access depend on the commercial agreement. Set those terms before the expensive development work begins.

A better way to measure formulation progress

Count closed decisions, not samples shipped.

A project is moving when the team has resolved formula feasibility, ingredient qualification, claims, specification, packaging, process, testing, and scale. A sixth flavor sample is not progress if the serving size is still impossible to manufacture.

Start a custom formulation brief, or compare OEM, ODM, and private label before choosing the development route.